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Rat mesaagial cells in vitro synthesize a spectrum of proteoglycan
species including those of the basement membrane and interstitium.
Accumulation of extracellular matrix within the mesangium is an impor-
tant event in thc development of glomerular disease. In this report we
have used indirect immunofluorescence to positively identify a number of
constituents of the mesangial matrix synthesized by rat mesangial cells
(RMC) in vitro including laminin, fibronectin, type IV collagen and the
basement membrane heparan sulphate proteoglycan (BM-HSPG) known
as perlecan. In addition, using Mab 2B5 we demonstrate that RMC
synthesize a specific basement membrane chondroitin sulfate (BM-
CSPG), a matrix component that in normal animals is localized in the
mesangium but is not found in the pericapillary glomerular basement
membrane (GBM). Further characterization of the proteoglycans synthe-
sized by RMC in vitro revealed: (i) a second large CSPG, identified as
versican; (ii) two small dermatan sulphate proteoglycans identified as
biglycan and decorin, which together account for the majority of the
proteoglycans; (iii) a large HSPG-I, probably related to perlecan; and (iv)
a small HSPG-II. The cell layer proteoglycans can be sub-divided into a
class that are probably free in the membrane, and a class of anchored
molecules of the extracellular matrix or stabilized by cytoskeletal ele-
ments.
The extracellular matrix (ECM) of the renal glomerulus serves
two critical functions: structural support and maintenance of a
permselectivity filtration barrier. This dual function results from
the physical and biochemical properties of the primary compo-
nents of the renal ECM. The structural elements are produced
and secreted locally by all endogenous glomerular cells and
consist of three types of macromolecules: collagens, glycoproteins
and proteoglycans [1], These molecules are organized into two
distinct matrices, the glomerular basement membrane (GBM)
and the mesangial matrix (MM). The GBM is synthesized by the
intrinsic glomerular epithelial and endothelial cell types and
consists primarily of type IV collagen as the major protein
together with varying amounts of laminin isoforms and heparan
sulphate proteoglycan [2, 3]. It is uncertain whether fibronectin is
embedded in this structure, but from a comparison with epithelial
basement membranes this seems unlikely. The MM is derived
from the mesangial cell. The normal glomerular mesangial cells
synthesize several ECM components, including type IV and V
collagen, laminins, fibronectin and proteoglycans [4]. In contrast
to the GBM the MM appears to contain a number of different
proteoglycans. For example, using a combination of enzymatic
digestion and autoradiographie methods it has been demonstrated
that while heparan sulphate is the predominant glycosaminogly-
can, chondroitin sulphate/dermatan sulfate (CSIDS) chains are
also present in significant amounts [5—7]. More recently, immu-
nohistochemical studies using well-defined monoclonal antibodies
to a basement membrane specific chondroitin sulfate proteogly-
can stained the mesangium but not the GBM [8].
In certain clinical glomerular diseases such as IgA nephropathy
and diabetes mellitus the mesangial matrix is frequently ex-
panded. In experimental models of renal disease there is some
evidence that glomerular proteoglycan metabolism may be per-
turbed [9—13] and also those proteoglycans associated with the
mesangium [14]. Therefore a detailed knowledge of the proteo-
glycans that make up the MM could be potentially important in
understanding the progression of renal disease. In this report
immunohistochemical and biochemical analyses show that RMCs
in culture contain and secrete basement membrane components
including a specific chondroitin sulfate proteoglycan. We also
describe the structural characteristics of several other proteogly-
cans species isolated from the cell layer and the culture medium
of cultured RMC. These molecules consist of predominantly
chondroitin/dermatan sulfate chains of which nearly two thirds are
accounted for by two small dermatan sulphate proteoglycans,
biochemically related to biglycan and decorin.
Methods
Chemicals and antibodies
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All chemicals used in the study were obtained from Sigma
Chemical Co. (Poole, Dorset, UK) unless otherwise indicated.
Protein U Sepharose, Sephadex G-25 Superfine and Sepharose
CL-4B were obtained from Pharmacia Fine Chemicals (St Albans,
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Herts, UK). Affi-Gel HZ was obtained from Bio-Rad Laborato-
ries (Richmond, CA, USA). The characterization of monoclonal
antibodies 2B5 and 2D6, which are specific for the core protein of
basement membrane-specific chondroitin sulphate proteoglycan
has been reported previously [8]. A further polyclonal antiserum
(R665) was raised against a portion of the BM-CSPG core protein
expressed as a fusion protein with glutathione 5-transferase using
the pGEX expression system (Pharmacia). A non-immune mouse
IgG was obtained from Jackson Immunoresearch (West Grove,
PA, USA). Rabbit anti-bovine decorin and biglycan, and rabbit
anti-bovine versican were the kind gift of Prof. D. Heinegard,
Upsalla, Sweden. The versican antiserum was raised against a
large CSPG isolated from bovine aorta and does not cross react
with aggrecan isolated from bovine cartilage and sclera [15]. The
antisera to decorin and biglycan were prepared from bovine
sources as described by Heinegard et al [15] and Westergren-
Thorsson et al [16]. Mab 2B6 (anti C4 sulphated CSPG) and Mab
3B3 (anti- C6 sulphated CSPG) were the gifts of Dr. Bruce
Caterson (Chapel Hill, NC, USA). Mab 2B6 and Mab 3B3
recognize the unsaturated 4- and 6-sulphated disaccharides re-
maining after digestion of chondroitin sulphate proteoglycans
with chondroitin ABC lyase [7]. A monoclonal antibody (1 1B4) to
rat perlecan was prepared against a heparan sulfate proteoglycan
isolated from rat aortic smooth muscle. The antibody recognizes a
heparan sulfate proteoglycan, whose core protein was Mr —400 K
when detected in Western blots of rat aortic smooth muscle cells,
and rat L2 yolk sac cells. The antibody principally stains all
basement membranes of rat tissue so far examined by indirect
immunofluorescence microscopy. The polyclonal antibodies used
to locate laminin (R3), Type IV collagen (R5) and fibronectin
(R2) have been described previously [17, 18].
Establishment of RMC cultures
The methods for procurement and maintenance of homoge-
neous cultures of RMC have been reported in detail [19, 20].
RMC suitable for radiolabeling studies were prepared by cultur-
ing cells in RPMI 1640 medium supplemented with 20% fetal calf
serum, 10 ,g transferrin/ml, sodium selenite 5 ng/ml and 0.6 IU
insulin/mi. Cells between the third and fifth passages were used.
Indirect immunofluorescence microscopy
Immunostaining of rat renal glomerulus was performed as
previously described [8, 21, 22]. RMCs were grown on 8-chamber
slides (Lab-Tek) to 80% confluency (5 days), washed with PBS,
fixed in cold acetone/methanol (1:1) for 10 minutes at 4°C and air
dried. The fixed cells were washed once with PBS, stained for
laminin, fibronectin, type IV collagen, perlecan and BM-CSPG
and incubated with the appropriate fluorescein conjugated sec-
ondary antibody at 37°C in the dark.
Radiolabeling and proteoglycan extraction
Confluent cultures were extensively washed with phosphate-
buffered saline (PBS) and labeled with 50 iCi/ml [35S]-sulphate
(Amersham mt.; sp.act. 665 Ci/mmol) for 24 hours in fresh
medium containing 20% fetal calf serum and 10% of the normal
inorganic sulfate [23]. In some experiments cells were labeled with
20 JLCi/ml D-[6-3H]-glucosamine HC1 (Amersham Int; 20 mCi/
mmol) for 36 hours. After labeling, the culture media (CM) were
removed and the cells and extracellular matrix (CL) washed (x2)
with non-radioactive medium. The culture medium and washes
were combined and solid guanidine HCI (0.39 g/mi) and protein-
ase inhibitors added as described previously [23]. The CL was
extracted with 4% CHAPS/4 M-guanidine hydrochloride, pH 5.8,
containing the proteinase inhibitors listed above [231. In some
experiments the CL was first extracted with 2 mI/dish of 0.2%
Triton X-100, 25 m'vi Tris-HC1, pH 7.5, containing proteinase
inhibitors (to yield a cell lysate fraction) followed by 2 mi/dish of
1% wt/vol Triton X-100, 4 M urea, 25 mvt Tris HCI, pH 7.5, and
proteinase inhibitors to yield a cytoskeleton-matrix fraction as
described by Woods et al [24].
Proteoglycan analysis
The extracts from the CM and CL were passed over a Sephadex
G-50 (fine) column (1 >< 20 cm) equilibrated with 8 M urea, 20 mM
Bis-Tris HC1, pH 6.0, 0.5% wt/vol CHAPS, 0.15 M NaCl (urea
buffer). The material eluting in the void volume was applied to a
Mono 0 anion-exchange column (Pharmacia) equilibrated in
urea buffer and unbound labeled material removed from the
column by washing with 5 volumes of the same buffer. Bound
labeled material was then eluted with a continuous 0.15 to 1.5 M
NaCI gradient in the same solvent. This method separates 35
glycoproteins and 355-labeled proteins (eluted between 0.15 and
0.3 M NaCI) from 35S-iabeled proteoglycans (eluted with 0.75 to
1.5 M NaCI). Fractions of 0.5 ml were collected and aliquots
counted for radioactivity. 355-labeled proteoglycans were precip-
itated overnight at 4°C with three volumes of 1.3% wt/vol potas-
sium acetate in 95% ethanol in the presence of 50 pg/ml each of
carrier chondroitin sulphate and heparin. The precipitate formed
was washed once with 95% ethanol, dried over N2, redissolved in
water, aliquoted and stored at —20°C until required.
Analytical gel chromatography
Gel filtration chromatography of the labeled proteoglycans
were performed on analytical columns (0.006 x 1.5 m) of
Sepharose CL-4B equilibrated in 4 M guanidine HC1 50 mtvt
sodium acetate, pH 6.0, containing 0.5% wt/vol Triton X-100, 1
mM NaSO, and 0.05% NaN3 (dissociative GuHC1 buffer). The
void volume (V0) and the total volume (Vi) of each column was
determined with 3H-hyaluronan and 3H-giucosamine, respec-
tively.
The mesangial proteoglycans were also fractionated on a hy-
drophobic affinity column using the method of Woods et al [24].
Briefly 35S labeled PGs were buffer exchanged into 4 M GuHCI 20
mM Tris HCI pH 7.0 and mixed for 20 hours with 5 ml of octyl
Sepharose (Pharmacia) equilibrated in the same buffer. The
mixture was poured into a column and the nonbound material
collected. The column was then washed with starting buffer then
sequentially with 20 mrt Tris-HCI pH 7.0; 100 m NaCI, 20 mM
Tris-HC1 pH 7.0; 3.0 M NaCI, 20 mm Tris-HC1 pH 7.0 to remove
nonspecifically absorbed material. The absorbed proteoglycans
were eluted by the addition of 5 >< 5 ml aliquots of 4 M GuHCI 20
mM Tris HCI pH 7.0 containing; 0.1%, 0.5% or 1.0% vol/vol
Triton X-100.
Purification of IgG fractions from ascites fluid
Ascites fluid was made 1 m with respect to CaCl2, incubated
for two hours at room temperature and then overnight at 4°C. The
fluid was then centrifuged at 11500 rpm (Sorvall SA-60 rotor) for
60 minutes at 4°C, the supernatant diluted 1:1 in PBS and passed
twice over a 3 ml column of protein G-Sepharose. The column was
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then rinsed with PBS until the A280 showed no protein present.
The bound lgG was eluted with 0.1 M acetic acid, pH 3.0, the
eluent adjusted immediately to pH 7.0 with 1.0 M Tris, pH 9.0, and
dialyzed into 0.1 M sodium acetate, pH 5.5, 0.15 ai NaC1, 0.02%
NaN1 (coupling buffer).
Preparation of affinity columns
Monoclonal antibody 2B5 [8] and non-immune mouse IgG
were covalently coupled to an agarose support (Affi-Gel Hz)
through the carbohydrate present on the Fc portion of the
molecules according to the directions of the manufacturer.
Affinity-purification and characterization of mesangial cell
BM-CSPG
Affinity columns were equilibrated with PBS. Aliquots of [355]
labeled CM mesangial cell proteoglycans (see above) were gently
mixed with the affinity matrices for 48 hours at room temperature.
The columns were then extensively washed with PBS to remove
unbound radioactivity. Bound radiolabeled proteoglycans were
eluted with 3 ml of 3 M sodium thiocyanate, and the columns
regenerated by washing with 10 ml of PBS. The loading/elution
sequence was as follows: the non-immune mouse IgG column was
first loaded with the [355]-proteoglycan preparation, allowed to
incubate for 48 hours, the column drained and rinsed with 1 ml of
PBS. Both the flow-though and the 1 ml rinse were pooled then
loaded onto the 2B5 affinity column and incubated for 48 hours.
Both columns were then rinsed and eluted as described above.
The approximate mass of the [355]-labeled affinity-purified
proteoglycan was estimated by gel filtration on an analytical
Sepharose CL-4B column under dissociative conditions. To inves-
tigate the glycosaminoglycan chains, aliquots of the affinity-
purified radiolabeled CSPG was digested with chondroitin ACII
or ABC-lyase and the products chromatographed on a Sephadex
G-25 Superfine column (0.5 >< 3 cm) equilibrated in 20 m
Tris-HCI, pH 7.4, containing 1.0 M NaCI, 0.02% sodium azide.
Preparation of rat conditioned medium proteoglycans
Confluent RMC were maintained in RPMI media containing-
FCS which had been passed over DEAF Sephacel to remove any
exogenous bovine proteoglycans. Fetal calf serum (FCS-GAG)
prepared by this treatment resulted in good labeling and the
incorporation of radioactive sulfate was equal to conditions when
10% FCS is used in the culture medium and with the same pattern
of proteoglycans. Conditioned medium was harvested every three
days. The secreted proteoglycans from approximately I liter of
medium were isolated by DEAE and Mono Q ion exchange as
previously described [251. The isolation was followed and the
products quantitated using the dimethylmethelene blue procedure
of Farndale [26].
Aliquots of 500 jig were ethanol precipitated and incubated
with buffer alone 0.2 mU of proteinase free chondroitin ABC
lyase(ICN) [27, 28], or a combination of heparinase 1(25 mU), II
(50 mU), III (50 mU) (Grampian, Aberdeen, UK) as described by
Lyon and Gallagher [29].
Preparation and extraction of rat GBM
Glomeruli were isolated from 40 rat kidneys and a GBM
fraction prepared in the presence of proteinase inhibitors by
osmotic lysis and detergent extraction as previously described [20,
30]. The final GBM preparation was extracted twice with 6
M-guanidine hydrochloride, pH 5.8, containing 0.1% Triton X-l00
and proteinase inhibitors on an end-over-end mixer for 48 hours
at 4°C. and centrifuged at 15000 g for 15 minutes. The superna-
tants were pooled and dialysed against urea buffer before frac-
tionation on a DEAE-Sephacel column (1 cm X 5 cm). The
column was washed extensively with urea buffer to remove
unbound protein and then with 4 M guanidine HC1 to elute the
proteoglycans. For analysis aliquots of 100 jig were ethanol
precipitated and treated with heparinase I, II, or III as detailed
above.
Western blot analysis of RMC proteoglycans
SDS polyacrylamide gel electrophoresis was carried out using
either 3 to 12% or 5 to 15% gradient gels following the method of
Laemmli [31]. Transfer of analytes onto nitrocellulose and devel-
opment with streptavidin biotinylated alkaline phosphatase com-
plex has been described previously [25, 32].
Enzymatic and chemical methods
Glycosaminoglycan chains were released from intact PGs by
digestion overnight in 0.05 M sodium acetate, pH 6.4, with papain
at 65°C [33]. Chondroitin sulphate chains were digested with 0.125
U/mI of chondroitin ABC lyase or chondroitin AC-ll lyase in the
presence of proteinase inhibitors [27, 28]. Heparan sulphate
chains were depolymerized in ice-cold nitrous acid following the
method of Shively and Conrad [34, 35].
Results
Localization of basement membrane CSPG (BM-CSPG)
When sections of adult rat kidneys were labeled immunohisto-
chemically with monoclonal antibody Mab 2D6 an antibody raised
to rat Reicherts membrane CSPG [8] prominent staining was
apparent in the mesangium and on the basement membrane of
the Bowman's capsule (Fig. IA). No staining was evident along
the glomerular basement membrane. In contrast, specific anti-
HSPG antibody stained the GBM (Fig. 1B). These findings
confirmed earlier reports that basement membrane CSPG has a
discrete localization within the normal rat glomerulus [8, 14].
Immunohistochemical staining of confluent RMCs demon-
strated that all cells reacted positively but weakly for BM-CSPG
using Mab 2D6 (Fig. 2A) and also positively for basement
membrane HSPG (perlecan) (Fig. 2B). In addition the cells in
vitro stained positively for collagen type lv, fibronectin and
laminin-1 (Fig. 2 C-E). Laminin-1 showed similar, if not identical,
staining pattern to HSPG. Fibronectin was abundant both in the
matrix and intracellularly. Type IV collagen on the other hand
resembled BM-CSPG since it revealed a sparse distribution in the
matrix. However, some intracellular staining was observed. These
experiments served to show that in culture RMCs synthesize
several different matrix components including the specific BM-
CSPG not previously described.
Affinity-purification of 35S-labeled mesangial cell BM-CSPG
To confirm that RMCs in vitro synthesize BM-CSPG affinity-
chromatography experiments were undertaken with metabolically
labeled proteoglyeans. Confluent cells were cultured for 36 hours
with [355]-sulfate and the total [355]-labeled macromolecules
extracted from the culture medium (CM) and the cell layer (CL).
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droitin AC-li lyase completely digested this affinity purified 35S-
labeled proteoglycan indicating that it is a chondroitin sulphate
and not a dermatan sulphate proteoglycan.
We next carried out Western blot analysis on the total proteo-
glycan population isolated from the CM prepared from unlabeled
cells. For this, and subsequent Western blot analysis the FCS used
for the cell culture had been previously passed over DEAE-
Sepharose to remove bovine proteoglycans. The mesangial cell
proteoglycans were investigated by PAGE and Western analysis
before and after digestion with chondroitin ABC lyase and
electrophoresed under reducing conditions on 3 to 12% gradient
gels. After transfer to nitrocellulose the separated proteins were
probed with an antiserum raised against a fusion protein contain-
ing a portion of BM-CSPG core protein. The Western blot
revealed a minor band of approximately 200 K in the control, but
this band was greatly enhanced after lyase digestion of the sample
(Fig. 4 lanes 1 and 2). In addition a new band of approximately Mr
= 120 K was also revealed after digestion with the same lyase.
Similar experiments with heparinase treated samples confirmed
that BM-CSPG did not contain heparan sulphate chains and was
therefore not a hybrid proteoglycan. These results indicate that
BM-CSPG has a core-protein —P200 K and also suggests that a
small amount of core-protein is secreted into the culture medium
as a non-glycanated protein. The band at -120 K (Fig. 4. lane 2)
probably represents a fragment of the core protein.
Identification of other sulfated proteoglycans secreted by RMCs
Fig. 1. Basement membrane proteoglycan distribution in normal rat glomer-
uli detected by indirect immunofluorescence microscopy; (A) BM-CSPG and
(B) BM-heparan sulfate proteoglycan (perlecan). Glomerular basement
membrane lacks BM-CSPG but Contains perlecan (arrows). The scale bar
represents 50 sm.
The [355]-proteoglycans in these extracts were then separated
from radiolabeled glycoproteins and contaminating proteins by
ion-exchange chromatography on a Mono-Q column. The major-
ity of the [355]-labeled material (93% and 95% of the CM and the
CL, respectively) bound to this column and were subsequently
eluted with 1.5 M NaCI in urea buffer. The 355-proteoglycans
isolated from the CM were applied to an affinity column made by
coupling IgG preparations of morioclonal antibody 2B5 to an
agarose matrix (Methods). Of the total labeled proteoglycans
applied to this column 94% was recovered in the breakthrough
volume. The remaining 6% of labeled proteoglycans was recov-
ered by elution with 3 M sodium thiocyanate. In control experi-
ments no CM 35S-proteoglycans bound to an affinity column
prepared with non-immune mouse IgG. Affinity absorbed mate-
rial was then chromatographed on dissociative Sepharose CL-4B.
A single proteoglycan peak was obtained eluting at a Kay of 0.34
(Fig. 3). This proteoglycan was totally resistant to nitrous acid
degradation and digestion with heparinase. In contrast chon-
(a) Chondroitin suiphate/dermatan sulfate proteoglycans. The
above experiments indicated that in culture RMC synthesize
BM-CSPG, but that it accounted for only a relatively small
percentage of the total 35S-labeled proteoglycan population lo-
cated in the CM. Experiments were therefore undertaken to
identify the other labeled proteoglyans secreted into the culture
medium.
Preliminary experiments were undertaken to determine the
amount of chondroitin sulphate and heparan sulphates in the CM.
Samples were precipitated with ethanol then incubated with
chondroitin ABC lyase and the products analyzed by chromatog-
raphy on PD-b columns. This indicated that CS/DS chains
accounted for 75% 6% (N = 15) of the total 35S-labeled
proteoglycans present in the CM while HS chains accounted for
the remainder.
To examine the nature of the CSPGs a portion of the CM was
alcohol precipitated, the HS chains removed with nitrous acid and
the remaining CS proteoglycans separated into two fractions on a
dissociative Sepharose CL-4B column (Fig. 5). A minor pool
(— 8% of the total proteoglycans synthesized by the cells) eluted
near the void volume (M-I; peak Kay = 0.05) while the majority
of the labeled proteoglycans (57% of the total synthesized by the
cells) eluted as a heterogeneous population at a more included
volume (M-II; peak Kay =0.35). The fractions M-I and M-II were
pooled separately and digested with chondroitin ABC lyase or
chondroitin AC II and the products analyzed by chromatography
on Sephadex G-50. Chondroitin ABC lyase and chondroitin AC II
lyase were equally effective in degrading the GAGs in M-I. This
pooi therefore represents a large CSPG and is designated
CSPG-I. The 35S-GAG chains in M-II also were completely
degraded by the ABC lyase but were 75% resistant to chondroitin
AC-li lyase indicating the presence of iduronate residues in the
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Fig. 2. Indirect immunofluorescence micrographs of RMC cultures stained with antibodies to (A) BM-CSPG, (B) HSPG (perlecan), (C) type IV collagen,
(D) fibronectin, (E) laminin and (F) secondaty antibody alone. Magnification x 350.
GAG chains. The M-II pooi must therefore contain a significant
proportion of DSPGs.
The M-II pool of DSPGs were subjected to a second Mono Q
ion-exchange purification step and eluted with a linear NaC!
gradient. This procedure separated the 35S-PGs into two poois
(Fig. 6A). SDS PAGE across the column followed by fluorography
also showed two populations of PGs (Fig. 6B); the lower charged
with an approximate Mr = 100 K and the higher charged
molecules of approximately Mr 200 to 250 K. The mono Q
fractions pooled as shown in Figure 6A were chromatographed on
Sepharose CL-4B. The lower charged (peak A), eluted with a Kay
= 0.4 (designated DSPG-II) while those with higher charge (peak
B), eluted with a Kay of 0.28 (designated DSPG-I) (Fig. 6C).
DSPG-I and DSPG-II were both resistant to digestion with
chondroitin AC-Il lyase and are therefore clearly different from
the BM-CSPG (Fig. 3).
The above results are consistent with the presence of CS/DS
proteoglycans biochemically related to versican, decorin and
biglycan. To further investigate these molecules a panel of anti-
bodies was used to analyze the CM proteoglycans and the
resulting Western blots are shown in Figure 7. The immunoblot-
ting of the proteoglycans separated by SDS-PAGE before and
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1 2 3
Fig. 4. Western blot analysis of BM CSPG in RMC culture medium.
Purified extracts of RMC derived PGs were subjected to gradient 3 to 12%
SDS-PAGE before (lane 1) and after (lane 2) digestion with chondroitin
ABC lyase, electroblotted onto nitrocellulose and probed with a poly-
clonal (rabbit) antibody recognizing a GST fusion protein containing a
portion of rat BM-CSPG core protein. Lane 3 is chondroitin ABC lyase
alone.
after chondroitin ABC lyase digestion showed that the Mabs 3B3
and 2B6 recognized different proteoglycans; the former showed
immunoreactive material similar to the core protein of versican
(Mr ---400 K; Fig. 7A, lane 2) whereas the latter identified an
abundant polypeptide of Mr —-—49 K (lane 4). Mab 2B6 but not
Mab 3b3 also identified a second minor band with an apparent Mr
——100 K. For a more precise understanding of the core proteins
further blots were probed with antibodies against versican, bigly-
0 0.2 0.4 0.6 0.8 1.0
Fig. 5. Sepharose CL-4B elution profiles of [35S] labeled CS/DS proteogly-
cans synthesized by RMC in culture. RMC were labeled with 35S-sulphate.
The labeled macromolecules extracted from the CM were processed on a
Mono Q column as detailed in the Methods section. The proteoglycan
pool was treated with nitrous acid and chromatographed on a Sepharose
CL-4B column. The fractions indicated were pooled for further analysis.
can and decorin [15, 16]. A positive reaction of the 400 kD
polypeptide (Fig. 7A, lane 6) was observed with an antiserum to
versican, while as expected, the core proteins at 49 kD were
identified as biglycan and decorin (Fig. 7B, lanes 2 and 4). None
of the versican, decorin or biglycan antibodies reacted with the
minor band at 100 kD, a polypeptide detected with the carbohy-
drate specific Mab 2B6.
(b) Heparan sulphate proteoglycans. To investigate the heparan
sulfate PGs in the CM the 35S-proteoglycans resistant to chon-
droitin ABC lyase digestion were resolved on a Sepharose CL-4B
column. The majority of the labeled HSPGs eluted with Kay
0.35 (Mr ——200K) (Fig. 8). The free glycosaminoglycan chains
released from this proteoglycan were totally degraded with nitrous
acid or a mixture of heparinase I, II and III, indicating that this
glycoconjugate is a HSPG (designated HSPG-1I). In addition
some heparan sulphate material eluted near the V0 of the CL-4B
column. This species was present as a minor component (1% of
the total) and is designated HSPG-I (Table 1). To examine
whether these HSPGs were related to BM-HSPG (perlecan)
aliquots of unlabeled CM proteoglycans were incubated with
heparinase or buffer alone and the released core-proteins probed
by immunoblotting with Mab 11B4. For comparison extracts of
rat-GBM were also investigated. Mab 11B4 recognized HSPG
core proteins only after removal of the HS-chains with depoly-
merizing enzymes. Polypeptides of ——Mr = 300 K, 260 K and 230
K were detected (Fig. 9, lane 2). Virtually identical polypeptides
were also observed in extracts of rat GBM (Fig. 9, lane 4). In the
GBM extract the major polypeptide had an Mr = 230 K whereas
in the RMC-CM that of ——Mr = 300 K was prominent.
Characterization of the cell layer 35S PGs
The PGs extracted from the cell layer with 4 M-guanidine
HC1/Triton X-100 were also analyzed by the same chromato-
graphic procedures as those used above for the CM and the
35S-labeled PGs identified included in Table 1. They contained a
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Fig. 3. Analysis of BM-[35SJ CSPG. The affinity purified BM-CSPG
isolated from the culture medium as described in the Methods section was
chromatographed on a dissociative Sepharose CL-4B column.
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A Fig. 6. Purification of RMC 35S-DSPGs. (A) The M-IL fraction (see Fig. 5)
800 1.3 was buffer exchanged into urea buffer containing 0.15 M NaCI and applied
to a mono 0 column. The column was washed with 0.75 M NaC1 and the
PGs were eluted with a linear 0.75-1.5 M NaCl gradient in the same buffer;
1.2 (B) Alternate fractions [16—281 across the mono Q column were alcohol
600 precipitated and electrophoresed under reducing conditions on a 3 to 12%
gradient SDS PAGE gel. The gels were impregnated with Amplify and a
fluorograph developed using Hyper-fllm (Amersham tnt PLC UK); (C)
The peaks designated A and B in (A) were pooled as indicated and
400 1.0 0 chromatographed on a dissociative Sepharose CL-4B column equilibrated
o with GuHC1 buffer. The PGs in pool A (•) were designated DSPG-II and
0.9 from pool B (0) DSPG-I.
200
0.8 high percentage of free glycosaminoglycan chains. To determine
whether this material was intracellular, mesangial cells were
0 0.7 labeled as above and the cell layer incubated with PBS containing
0 10 20 30 40 50 trypsin (10 1.tglml) or buffer alone. The material remaining
associated with the CL consisted predominantly of 35S-labeledFraction number glycosaminoglycans (Kay > 0.5; CL-4B) whereas the molecules
released by trypsin eluted from the same column with a Kay =
0.35 indicating that they were derived from intact proteoglycans
(data not shown). This suggested that the proteoglycans accessible
to trypsin are associated with the cell membrane.
B To further investigate this, the CL 35S-PGs were buffer ex-
changed into 4 M GuHC1 20 mrvi Tris HCI pH 7.0 and fractionated
on the basis on their affinity for the hydrophobic medium octyl-
Sepharose (Methods), The fractions obtained were then analyzed
205 on Sepharose CL-4B after incubation with chondroitin ABC lyase
or nitrous acid.
116 Approximately 33% of the CL 35S-proteoglycans failed to bind
to the octyl Sepharose and comprised free glycosaminoglycan80 * chains (HS 20% and CS/DS 80%). In addition, this fraction also
contained all of the cell layer CSPG-I (versican) together with
49 —* some DSPG-II (Fig. bA).
The bound material was composed of CS/DS (52%) and HS32 (48%) proteoglycans from which HSPG-1l could be separated
from the larger HSPG-I and from the cell layer DSPGs (compare
Fig. lOB with C) by stepwise elution with buffer containing
detergent. Thus the more hydrophobic material eluted with 0.5%
(vol/vol) Triton X-100 contained only HS-chains and eluted at
1 2 3 4 5 6 7 Kay 0.35 consistent with HSPG-II (Fig. bC). This finding sug-
gests that HSPG-II is associated with the plasma membrane.
c The CL labeled PGs were also studied using an extraction
800 protocol which distinguishes the PGs of the cell membrane andintracellular compartments (cell lysate) from those of the matrix
and/or retained by the cytoskeletal elements (cytoskeleton-ma-
E trix) [241. Thus mesangial cells pre-labeled with 35S-sulphate were600 extracted with 0.2% Triton X-l00, 10 mr'i Tris-HC1, pH 7.6, to
yield a cell lysate and the remaining detergent resistant material
was solubilized with 1% Triton X-100, 4 M urea buffer to yield a
400 cytoskeleton-matrix. Analysis of each extract indicated that the
cell lysate and cytoskeleton-matrix contained different proteogly-
cans (compare Fig. 11 A with B). The cell lysate included
200 HSPG-II and DSPG-II together with free GAG-chains (Fig.
hA), whereas the cytoskeleton-matrix extract was made up of
CSPG-l, HSPG-I and DSPG-I (Fig. IIB). The distribution of the
0 different PGs identified by octyl Sepharose chromatography and
0.0 0.2 0.4 0.6 0.8 1.0 selective extraction are listed in Table 2.
Discussion
In the present paper we show that rat MC synthesize predom-
inantly CS/DS proteoglycans. A number of different species were
Kay
Mr
kDa
205 —0
116 —'
80 —o
49 —0
32 —0
B Mr
kDa
160 —0
80 —0
49 —0
32 —'
27 —0
18 —0
1 2 3 4 5 6
1 2 3 4
•fr S
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Fig. 8. Sepharose CL-4B elution profiles of f35SJ labeled HS proteoglycans
synthesized by RMC in culture. The proteoglycan pool (see Fig. 5) was
treated with chondroitin ABC lyase and chromatographed on a Sepharose
CL-4B column. The inserts show flurographs of HSPG-I and HSPG-II on
3 to 12% gradient SDS-PAGE.
Table 1. Inventory of RMC [35S1-labelled proteoglycans
Species Kay Location % totaP
CSPG-I 0.05 CM/CL 8.3/1.4
BM-CSPG 0.34 CM 6.0
DSPG-I 0.28 CM/CL 21/3.0
DSPG-II 0.40 CM/CL 19.7/7.5
CS/DS-GAGS 0.6-0.7 CL 8.5
HSPG-I 0.15 CM/CL 1.0/1.2
HSPG-I1 0.35 CM/CL 14.5/5.0
HS-GAGS 0.6—0.7 CL 2.3
a The distribution is calculated for the total 35S-PG synthesized by the
cell over 24 hours (that is CL +CM) and is presented as percent of this
total.
Fig. 7. Western blot analysis of CS/DS PG in RIvIC culture medium.
Purified extracts of RMC derived PGs (see Fig. 4) were subjected to (A)
gradient 3 to 12% SDS-PAGE or (B) 5 to 15% before (lanes 1,3 and 5)
and after (lanes 2, 4 and 6,) digestion with chondroitiri ABC lyase,
electroblotted onto nitrocellulose and probed with monoclonal antibodies
to (Fig. 7A) chondroitin-6 sulphate (Mab 3B3) (lanes I and 2); chon-
droitin 4-sulfate (Mab 2B6) (lanes 3 and 4) and polyclonal antibodies
against versican (lanes 5 and 6) and (Fig. 7B) decorin (lanes 1 and 2);
biglycan (lanes 3 and 4).
identified including: a large molecular weight CS proteoglycan; a
relatively small basement membrane CSPG and three small
CS/DS proteoglycans.
Previous in vitro studies on proteoglycan synthesis by whole
glomeruli and mesangial cells have focused on the small DS
proteoglycans [36—401. In the present study we identify two such
molecules which collectively account for 73% of the total 35S-
proteoglycan population synthesized by these cells. Although a
small amount of these DS proteoglycans were present in the
detergent extract of the cell layer the majority of these molecules
were located in the culture medium. Based on the biochemical
data two of the secreted forms of these molecules were non-
hydrophobic, had an apparent Mr of 250 kD and 150 kD with core
protein of 42 to 45 kD. Similar DS proteoglycans have been
extracted from other renal cells as well as nonrenal cells and
extracted from various tissues [reviewed in 411. They belong to the
small interstitial proteoglycan family of which biglycan and
decorin are the best documented [42, 43]. The sequences of these
two small dermatan proteoglycans have been determined by direct
peptide analysis and from cDNA clones. They contain from 8 to
12 consecutive leucine-rich repeating sequences. Biglycan con-
tains two Ser-Gly dipeptides which serve as attachment sites for
glycosaminoglycans, whereas decorin is commonly substituted
with one chain. This difference in chain density probably accounts
for the partial separation by anion-exchange chromatography of
DSPG-I and DSPG-II in our experiments. The molecular mass of
these two molecules (Fig. 6) taken together with the immunoblot
data (Fig. 7) strongly suggests that DSPG-I and DSPG-II are
biglycan and decorin, respectively. Okuda and co-workers [1
have also reported that RMCs secrete both these small PGs. We
also detected a putative third small DSPG using a monoclonal
that recognise DSPGs after chondroitinase digestion by virtue of
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Mr 400
kDa
300
1 2 3 4 5
Fig. 9. Western blot analysis of HSPGs synthesized by RMC in vitro and
extracted from rat GBM. Purified extracts of RMC derived PGs (see Fig. 4)
and an extract of rat GBM were subjected to 3 to 12% SDS-PAGE before
(lanes I and 3) and after (lanes 2 and4) digestion with heparinase I, II and
HI, transferred to nitrocellulose and probed with Mab 1 1B4. Lafles 1 and
2, RMC extract; lanes 3 and 4, GBM extract; lane 5, heparinase I, II and
III only.
reaction with carbohydrate stubs containing chondroitin-4 sulfate
[71. This PG had a core protein of about 100 kD and may be
related to PG-100 a recently described proteoglycan which may be
related to the small interstitial family of proteoglycans [41, 45].
The detection of both decorin and biglycan in the culture
medium and to a lesser extent on the cell layer is of interest since
studies on the tissue distribution of these PGs suggest that they
may be different. In particular, in the developing kidney biglycan
but not decorin was localized in the glomerulus [461. Further fetal
human mesangial cells also only appear to produce biglycan [37].
In contrast, mesangial cells derived from adult human kidney
synthesize both biglycan and decorin [32].
Proteoglycans with properties similar to CSPG-I have not been
described previously in RMCs. However a class of large CSIDS
proteoglycans (Mr> 106; protein core Mr = 200 to 500 K) have
been characterized from several sources including aortic smooth
muscle cells and fibroblasts [15, 47—49]. The complete amino acid
sequence of the large fibroblast CSPG (versican) has been de-
duced from cloned cDNAs [501. The core protein contains at its
N-terminus a hyaluronic acid-binding motif while the C-terminus
contains two epidermal growth factor-like repeats, a lectin-like
sequence and a domain homologous with complement regulatory
protein. RMC-CSPG-I was shown to be identical to, or immuno-
logically related to versican. Consistent with this, the antibody
recognizing chondroitin-6-sulphate in the context of its carbohy-
drate "stubs", but not that recognizing chondroitin-4-sulphate
recognized the versican core protein. Analysis of blood vessel
versican has shown the presence of large amounts of the 6-sulfate
chondroitin sulfate [511. We have also recently reported that a
similar CSPG made by human mesangial cells in vitro is immuno-
A
205 —*
116 —k
80 —*
49 —,-
32 —*
200
100
0
600
500
E
. 400
ii 300
200
C/)I')
Co
100
0
1,000
800
600
400
200
0
Fig. 10. Separation of CL [ 355]-labeled PGs on an oclyl Sepharose affinity
column. Labeled PGs were extracted from the CL and passed over an octyl
Sepharose column as detailed in the Methods section. The non-bound (A),
0.1% Triton X-100 clutate (B), 0.5% Triton X-100 eluate (C) were
chromatographed separately on a Sepharose CL-4B column. The hatched
areas in (B) and (C) indicate proteoglycans resistant to digestion with
chondroitin ABC lyase (that is, HSPGs).
0 0.2 0.4 0.6 0.8 1.0
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Fig. 11. Differential extraction of RMC cell associated PGs. Labeled PGs
were extracted from the CL with (A) 0.2% Triton X-100 (cell lysate)
followed by (B) 1% Triton X-100 in 4 M urea (cytoskeleton-matrix) and
the extracts chromatographed separately on a Sepharose CL-4B column.
The hatched areas indicate proteoglycans resistant to digestion with
chondroitin ABC lyase (that is, HSPG5).
logically related to versican and specifically binds hyaluronate, in
contrast to decorin, biglycan and heparan sulfate PGs [25].
The results presented in this work are the first to demonstrate
that mesangial cells in culture synthesize a specific basement
membrane CSPG. This proteoglycan was isolated from the culture
medium by affinity chromatography using a defined monoclonal
antibody which immunostains the mesangial matrix but not the
GBM [8]. The glycosaminoglycan chains of this affinity-purified
molecule were totally degraded by chondroitin ACII lyase, thus
confirming that it is unrelated to either of the small DSPGs
discussed above. Immurioblotting of the chondroitin ABC lyase-
digested total proteoglycan from CM with a polyclonal antibody
against a fusion protein for BM-CSPG showed the core protein to
have molecular mass of 200 kD. Thus the core protein is clearly
different from that determined for versican, the mostly likely
identity of the large CSPG-I, and those recorded for decorin and
biglycan. The value of 200 kD, however, is slightly larger than the
affinity purified CSPGs from rat Reichert's membrane and whole
kidney [81. The reason for this discrepancy is not known, but it
could be related to the degree of N-and 0-linked substitution
Table 2. Distribution of RMC cell layer 35SPGa
Method Proteoglycan
Octyl Sepharose
chromatography
Non-bound CSPG-I(1.4); HS-GAG(2.3;DS/CS-GAG(8.5)
0.1% Triton DSPG-I(3.0); DSPG-II(7.5); HSPG-I(1.2)
0.5% Triton HSPG-Il(5.0)
Selective extraction
Cell lysate HSPG-II(5.0); DSPG-II(7.5); HS-GAG(2.3);
CS/DS-GAG(8.5)
Cytoskeleton-matrix CSPG-I(1 .4); DSPG-I(3.0); HSPG-I(1.2)
a The figures in parentheses indicate the distribution of the labelled PG
recovered in the fraction expressed as a percent of the total 35S-PG
population (see Table 1).
achieved in vitro. This apart the biochemical and immunohisto-
logical localization strongly suggest that RMCs synthesize the
BM—CSPG, known to be increasingly abundant in the course of
mesangial expansion in streptozotocin treated rats [141.
The selective extraction of the mesangial cell layer with deter-
gent suggests that the cell associated proteoglycans can be subdi-
vided into a class that are probably free in the membrane, and a
class of anchored molecules of the extracellular matrix or stabi-
lized by cytoskeletal elements. Proteoglycans are found on the
surface of most, if not all, cultured cells. Although these include
CSIDS proteoglycans, HS proteoglycans are by far the most
abundant. Based on the data presented in Table 1, HSPG-II and
DSPG-II (decorin) appear to occur as cell membrane-associated
forms in RMCs. In addition both these proteoglycans bind, but
with different affinities, to octyl Sepharose, indicating that they
may contain a hydrophobic binding region. The amino acid
sequence of decorin, however, does not contain a transmembrane
sequence [42]. Thus the extraction of this DSPG-II with detergent
alone is probably due to a peripheral association of this molecule
with a cell membrane receptor [52—55]. Endocytosis of decorin in
human fibroblasts is mediated via a cell membrane receptor that
recognizes the core protein. Data from pulse-chase experiments
indicate that DSPG-II after synthesis is rapidly lost from the cell
layer, a portion of which is recovered in the culture medium while
the remainder is metabolized intracellularly with the liberation of
free sulfate (Shewring and Davies, unpublished results).
In our study we were able to distinguish two 35S-labeled HSPGs
on the basis of their hydrodynamic size, cellular location and
affinity to octyl Sepharose. Thus HSPG-I (Mr _106) was extracted
from the cytoskeleton-matrix and bound weakly to octyl Sepha-
rose. In contrast HSPG-I1 (Mr —200 K) was associated with the
cell lysate and clearly possessed hydrophobic properties. Analysis
of unlabeled HSPGs extracted from the CM with antibodies to
perlecan revealed a number of core protein bands all of which had
Mr > 200 K. Since similar bands were obtained with partially
purified extracts of rat GBM it is likely that HSPG-I rather than
HSPG-II represents BM HSPG (perlecan). It is possible that
HSPG-II is a cell membrane associated PG(s) related to either the
syndecan or glypican families of HSPGs [56].
The biological relevance of the different proteoglycans synthe-
sized by glomerular mesangial cells has not been clearly defined.
The ability of decorin to bind to and neutralise the biological
activity of TGF-/3 led Border and colleagues to suggest that
decorin is a potential factor in the expansion of the mesangium in
A HSPG-lI/DSPG-ll
FREE GAG
DSPG-I
0
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progressive glomerular disease. Indeed, these workers have re-
cently shown in an experimental model of mesangioproliferative
glomerulonephritis that infusion of recombinant decorin pre-
vented the increase production of ECM. Decorin and also bigly-
can appear to have functional roles in regulating collagen fibril-
logenesis but such a function within the glomerulus is difficult to
envisage. Large CSPGs such as versican have been suggested to
play a role cell migration and proliferation of vascular smooth
muscle cells. In normal rat kidney BM-CSPG is clearly restricted
to Bowman's capsule and the mesangium and is absent from the
GBM [81 but in diseased kidney this distribution is altered and the
BM-CSPO becomes abnormally associated with the pericapillary
GBM [14] The present finding that RMCs in vitro synthesize
BM-CSPG as well as perlecan is an intriguing finding, since it
presents an experimental approach to study the metabolism of
different (IBM proteoglycans.
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